1 Actuarial 1 and 3 year survival was 88% and 50% respecti
2 The
actuarial 1, 2, 3, and 4 years patient and graft surviva
3 The
actuarial 1-, 2-, and 3-year survival rates posttranspla
4 Actuarial 1-, 3-, and 5-year overall survival rates were
5 years (range, 1 to 12.9 years), with overall
actuarial 1-, 3-, and 5-year survival rates of 70%, 36%,
6 Actuarial 1-, 3-, and 5-year survivals were 85%, 60%, an
7 P=NS), early rejection (21 vs. 18%, P=NS) or
actuarial 1-year graft survival (96 vs. 90%, P=NS).
8 Actuarial 1-year graft survival was 91.7% with sirolimus
9 Actuarial 1-year overall survival (OS) and event-free su
10 The
actuarial 1-year pancreas graft survival was 87% for the
11 Actuarial 1-year patient and graft survival were 98.6% a
12 Actuarial 1-year patient survival was 91.7% with sirolim
13 The
actuarial 1-year patient survival was 93% for the PAK gr
14 nths (interquartile range, 3.1-37.1 months),
actuarial 1-year survival of 47.6%, and 2-year survival
15 se, and 8 (8%) underwent biopsy only with an
actuarial 1-year survival of 88%, 51%, and 47%, respecti
16 ents with a median follow-up of 11 years had
actuarial 10- and 15-year overall IBTR rates of 22% and
17 Actuarial 10-year disease-free survival was significantl
18 gins of <1 mm, 1 to 9 mm, and >or=10 mm, the
actuarial 10-year IBTR rates were 28%, 21%, and 19%, res
19 Death-censored
actuarial 15-year graft survival rate was 56%.
20 Actuarial 15-year graft survival was 71% for nonrecurren
21 Estimated 5-year, 10-year, and
actuarial 15-year overall patients survival rates were 7
22 For living donor recipients, the
actuarial 15-year PS rates were similar between groups.
23 Actuarial 15-year survival was 60.6% (95% CI, 56.3%-64.9
24 xperienced BPAR (including borderline), with
actuarial 19% (14/75) vs. 18% (13/75) in groups A and B,
25 Actuarial 2-, 5- and 10-years overall- and disease-speci
26 Actuarial 2-year patient, graft, and rejection-free graf
27 The
actuarial 2-year rates of locoregional control and disea
28 tal bone volume of more than 37.3% showed an
actuarial 2-year survival of 18%, compared with 82% for
29 followup of 34 months in the survivors, the
actuarial 2-year survival was 47%, the median survival w
30 The
actuarial 20-year patient survival rate was 38%; graft s
31 Actuarial 20-year survival was 52% (patient) and 42% (gr
32 The
actuarial 20-year survival was estimated at 45%.
33 The
actuarial 3-year cancer-specific survival rate was 57% (
34 The
actuarial 3-year event-free and overall survival rates w
35 With a median follow-up of 37 months, the
actuarial 3-year relapse-free survival rate is 24% for t
36 The
actuarial 3-year relapse-free survival rate was 30% (95%
37 The estimated
actuarial 3-year survival of patients who survived at le
38 Actuarial 3-year survival rate was 30% after FAI and 35%
39 The
actuarial 3-year survival was 17%.
40 The
actuarial 4-month risk of death was 8.9%, 1.9%, and 1.2%
41 The
actuarial 4-year progression-free and overall survivals
42 The
actuarial 4-year survival rate for the entire group was
43 Actuarial 5- and 10-year survival was 52% and 43% (HTV o
44 The
actuarial 5- and 10-year survivals for patients who unde
45 Actuarial 5-year disease-free survival was 75% and five
46 odal disease at presentation had a decreased
actuarial 5-year disease-specific (0% v 45%, P =.004), d
47 Actuarial 5-year freedom from 2ndINT was 80%.
48 The
actuarial 5-year local and regional nodal control rates
49 This treatment resulted in an
actuarial 5-year local control and overall survival of 1
50 The
actuarial 5-year overall survival was 58% (95% confidenc
51 The
actuarial 5-year overall, disease-specific, disease-free
52 Actuarial 5-year patient survival was 94% in M and 95% i
53 After a median follow-up of 5.1 years, the
actuarial 5-year progression-free survival for all patie
54 The
actuarial 5-year survival for patients undergoing sphinc
55 Actuarial 5-year survival was 42% after resection for IP
56 adversely affect aneurysm-related or overall
actuarial 5-year survival.
57 te rejection in A2/A2B to B transplants, the
actuarial 7-year death censored graft survival was 72% f
58 The
actuarial 7-year disease-free survival rates were 81% an
59 The
actuarial 7-year overall survival rates were 85% for pat
60 pes individual variation in reproductive and
actuarial ageing in nature.
61 Standard techniques for
actuarial analyses of potential prognostic variables (Ka
62 In
actuarial analysis among the initially medically managed
63 By
actuarial analysis in newly diagnosed CLL (n = 306), BIR
64 Actuarial analysis showed an incremental risk of lead fa
65 At the final
actuarial analysis when follow-up data were updated (Nov
66 On
actuarial analysis, freedom from appropriate shock at 1
67 By
actuarial analysis, the 12-month TLR and MACE rates were
68 By
actuarial analysis, the TAXUS stent compared with the ba
69 ed with the development of PN by exploratory
actuarial analysis.
70 genotypes was determined using Kaplan-Meier
actuarial analysis.
71 On an
actuarial basis, the rate of neoplastic progression was
72 al clinical results are needed to complement
actuarial calculations of important end points from mult
73 The 10- and 15-year
actuarial cause-specific survival rates were 98.1% and 9
74 The
actuarial chance of not needing chemotherapy (non-lympho
75 Based on
actuarial characteristics of the 2002 U.S. population, p
76 The
actuarial complication-free survival rate was 71%.
77 The 5-year
actuarial cumulative rate of BKVN was 5.6%.
78 The
actuarial current progression-free survival (PFS) rate a
79 The dissimilarity of
actuarial curves between these two groups is consistent
80 y to Enhance Survival database for 2016, and
actuarial data for remaining life expectancy at the age
81 Two-year
actuarial data showed a 75% local tumor control rate and
82 ced relative to historical controls based on
actuarial data.
83 Five-year
actuarial disease-free and overall survival rates were 8
84 e-year PFS was 22% (95% CI, 12%-32%); 5-year
actuarial distant metastasis and locoregional recurrence
85 vival (OS), progression-free survival (PFS),
actuarial distant metastasis, and locoregional recurrenc
86 At 24 months, the
actuarial estimate of stable treatment-free remission wa
87 Actuarial estimates for OS were calculated using Kaplan-
88 red the FLT3/ITD had worse clinical outcome;
actuarial event-free survival (EFS) at 4 years from stud
89 At 6 months, the
actuarial event-free survival (no acute rejection, allog
90 Actuarial event-free survival at 5 years was 70% versus
91 s, overall actuarial survival, response, and
actuarial event-free survival rates were 62%, 48%, and 2
92 1% with the majority being complete, and the
actuarial event-free survival was 58% in 44 treatment-na
93 However,
actuarial freedom from "heart death" (death or transplan
94 In early survivors,
actuarial freedom from death or transplantation was 93.7
95 patients implanted before 2000, the 4-month
actuarial freedom from driveline infections, bloodstream
96 Actuarial freedom from parenteral support among survivor
97 eratively (range, 3.6 to 30.6 months) for an
actuarial freedom from reoperation of 90% at 7 years.
98 served in the CMT group; in the RT group the
actuarial frequency of a second cancer was 16% at 20 yea
99 Actuarial graft and patient survival was similar in the
100 gnificant difference between groups in 15-yr
actuarial graft survival (GS) and death-censored (DC) GS
101 Actuarial graft survival at 1 and 4 years postconversion
102 The
actuarial graft survival at 6.3 years in the CAD DBMC gr
103 e did not observe significant differences in
actuarial graft survival at 8 yr post-transplant between
104 The 1, 3, and 5 year
actuarial graft survival in both living donor kidney aft
105 There is no difference in
actuarial graft survival in the two groups at 10 years (
106 The
actuarial graft survival in this group of 14 patients wa
107 n follow-up of 31 months, the death-censored
actuarial graft survival of dDSA recipients was worse th
108 ransplantation); corresponding 1- and 3-year
actuarial graft survival was 88% and 61%.
109 Subgroup
actuarial graft survival was determined.
110 no significant difference between groups in
actuarial graft survival.
111 The 8-year
actuarial graft survivals for the single- and dual-kidne
112 eriovenous malformations, but with increased
actuarial hemorrhage rates from the first to the fifth y
113 of these factors was associated with 5-year
actuarial IBTR-free and LRR-free survival rates of 87% t
114 Actuarial in-field local control rates at one and two ye
115 ths, 20 patients developed t-MDS/AML, for an
actuarial incidence of 6.8% at 10 years.
116 low-risk patients who were not screened, the
actuarial incidence of an IHD event after listing (befor
117 The 2-year
actuarial incidence of grade 3 to 5 radiation necrosis w
118 ter sparing procedure was 10% and the 5-year
actuarial incidence was 13%.
119 Kaplan-Meier estimates of the
actuarial incidence, which are based on censoring of pat
120 Observed survival was calculated by
actuarial life table methods for three new node-positive
121 Actuarial local control at one and two years after SBRT
122 The 5-year
actuarial local control rate was 94% (95% CI, 86% to 100
123 for all patients), the overall 3- and 5-year
actuarial local recurrence rates were 11% and 13%, respe
124 disease treated at M.D. Anderson, the 5-year
actuarial local recurrence-free, distant recurrence-free
125 The 3-year
actuarial locoregional control was 82% and the 3-year ac
126 zed survival of both blacks and whites using
actuarial measures; presented outcomes within stage, adj
127 er a median follow-up time of 53 months, the
actuarial median survival time of all eligible patients
128 The 5-year
actuarial metastasis-free survival estimates (SE) were 9
129 k group, PSA outcome was estimated using the
actuarial method of Kaplan and Meier.
130 ative survival also was calculated using the
actuarial method.
131 Overlooked is the question of whether such
actuarial methods are in fact mathematically justified,
132 st-feeding at 12 months was determined using
actuarial methods.
133 The
actuarial mortality rate was substantially lower among p
134 undergo transplantation or pump replacement,
actuarial mortality was 48.2% (95% CI, 31.6 to 65.2) in
135 increased mortality (including 1- and 5-year
actuarial mortality) around an eRVSP of 30.0 mm Hg was e
136 Diagnosis was based on the Jak-Bondi
actuarial/
neuropsychological approach.
137 Overall
actuarial one-year survival was 90%, and five-year survi
138 women with a first or only BC (BC-1 group),
actuarial OS and CSS were compared, accounting for age,
139 onths, median actuarial PFS is 17 months and
actuarial OS is 92 months.
140 and median OS was 47.4 months; 5 and 10-year
actuarial OS probabilities were 43% and 34%, respectivel
141 Our data suggests that 15-year
actuarial outcome (GS and DC GS) is worse for those deve
142 We analyzed the 15-year
actuarial overall patient survival (PS), graft survival
143 w-up of 36 months (range, 18-60 months), the
actuarial overall survival (OS) rates at 3 years were 34
144 The
actuarial overall survival and event-free survivals at 2
145 The
actuarial overall survival at 14 months was 53%, with a
146 Actuarial overall survival for the 1-, 2- and 3-year per
147 uing smokers (18 v 13.6 months), with 5-year
actuarial overall survival of 8.9% versus 4%, respective
148 Actuarial overall survival was calculated with Kaplan-Me
149 Actuarial overall survivals at 1-, 3-, and 5-year for th
150 Actuarial pancreas graft survival for SPK recipients at
151 In this series, 1-year
actuarial patient and allograft survival rates are 100%
152 Four-year
actuarial patient and graft survival for the DBMC-infuse
153 Actuarial patient and graft survival rates at 10 years w
154 Overall 5-year
actuarial patient and graft survival rates were 100% ver
155 Three-year
actuarial patient and graft survival rates were 95% and
156 One-year
actuarial patient and graft survival was 97% and 92%, re
157 Eight-year
actuarial patient and graft survivals in older individua
158 The overall 20-year
actuarial patient and graft survivals were 35.8% and 32.
159 The overall 20-year
actuarial patient and graft survivals were 35.8% and 32.
160 Overall 1- and 3-year
actuarial patient and liver allograft survival was 88% a
161 Three-year
actuarial patient and primary graft survival were 88% an
162 nance immunosuppression had excellent 4-year
actuarial patient survival (92%), graft survival (90%),
163 Actuarial patient survival at 1 and 3 years for group 1
164 Similarly,
actuarial patient survival at 10 years is 86% in both gr
165 The
actuarial patient survival rate at 3 years was 88%, and
166 Two-year
actuarial patient survival was 95% and 97%, and graft su
167 The 8-year
actuarial patient survivals for the single- and dual-kid
168 The 39-month Kaplan-Meier
actuarial patient survivals were 75.1% for CLTx and 88.6
169 The 1-year
actuarial patient, kidney, and pancreas survival rates i
170 Actuarial patient/graft survival at 48 months was 96%/91
171 One-year
actuarial patient/graft survival was 100%/100% in SPK, P
172 Three-year
actuarial patient/pancreas graft survival rates for SPK,
173 n potential follow-up of 28.3 months, median
actuarial PFS is 17 months and actuarial OS is 92 months
174 Actuarial-
predicted life expectancy, based on age and se
175 The primary end point was 2-year
actuarial primary tumor control; secondary end points we
176 The
actuarial probability of being alive and in remission at
177 a median follow-up period of 26 months, the
actuarial probability of current-event-free-survival at
178 The
actuarial probability of liver decompensation was lower
179 The
actuarial probability of PVT was lower in the enoxaparin
180 (69.6%) and 7 in group B (29%) survived; the
actuarial probability of survival at day 60 was 66% vers
181 The
actuarial probability of survival was higher in the enox
182 The
actuarial progression-free survival of 62% at 4 years is
183 Median
actuarial progression-free survival was 34 months.
184 an follow-up of 42 months, the 3- and 4-year
actuarial progression-free survivals were 71% and 62%, r
185 s no difference between groups in subsequent
actuarial PS, GS, and DCGS.
186 The 4-year
actuarial PSA relapse-free survival, distant metastasis-
187 9-43]), 44 (34%) had local regrowths (3-year
actuarial rate 38% [95% CI 30-48]); 36 (88%) of 41 patie
188 The
actuarial rate of CTCAE-free survival was not related to
189 locoregional control was 82% and the 3-year
actuarial rate of distant metastases was 19%.
190 lysis, factors significantly associated with
actuarial rate of first CVA included hypertension (P = .
191 tionships between potential risk factors and
actuarial rate of first stroke were analyzed.
192 The
actuarial rate of overall survival at 12 years was 76.3%
193 The
actuarial rate of R01 award attainment at 5 years was 22
194 By week 50, the
actuarial rate of treatment failure was 30.6% in the com
195 Actuarial rates of acute GVHD were 46% +/- 13% for grade
196 The 2-year
actuarial rates of elective nodal control and primary tu
197 Five-year
actuarial rates of IBTR-free and LRR-free survival were
198 Actuarial rates of LR were calculated by using the Kapla
199 The 5- and 10-year
actuarial rates of LRR were both 27%.
200 ce rate was 10.3% (23 of 223), with a 5-year
actuarial recurrence-free rate of 0.84 +/- 0.03.
201 was 2.3% (two of 86), resulting in a 5-year
actuarial recurrence-free rate of 0.96 +/- 0.03.
202 e Kaplan-Meier method was used to assess the
actuarial recurrence-free survival on patients with graf
203 ined rejection-free during follow-up with an
actuarial rejection-free probability of 75% within 3 mon
204 11 patients (
actuarial relapse at 5 years 5.6%, 95% CI 2.3-8.9) given
205 Actuarial renal allograft survival rates were 53% at 1 a
206 In contrast,
actuarial RFS rates for similar intervals were 79.1% (95
207 The
actuarial risk for this complication has been estimated
208 eatment-related parameters, crude and 2-year
actuarial risk of BM were 27% and 39%, respectively, in
209 Actuarial risk of death from stage I breast cancer at 7
210 Twenty-five years after HD diagnosis, the
actuarial risk of developing a solid tumor was 21.9%.
211 ed patients, progression-free survival (PFS;
actuarial +/-
SE) was 61% +/- 7% and survival was 58% +/
212 The
actuarial senescence (i.e., the rate of increase in adul
213 While previous research has demonstrated
actuarial senescence in this population, as does this st
214 Recent examples of
actuarial senescence in wild insect populations have cha
215 By contrast, analyses of
actuarial senescence showed no cost of early-life reprod
216 Among families of mammals,
actuarial senescence was related to extrinsic mortality
217 tion (reproductive senescence) and survival (
actuarial senescence) in most organisms.
218 d broods showed subsequent increased rate of
actuarial senescence, resulting in reduced residual life
219 terminal investment can produce a signal of
actuarial senescence.
220 n mechanisms that postpone physiological and
actuarial senescence.
221 can evolve in the absence of reproductive or
actuarial senescence; this implies that maternal effect
222 Actuarial survival after completed stage 2 was 71% at 5
223 Estimated
actuarial survival after continuous-flow left ventricula
224 Five-year
actuarial survival after heart transplantation was 58%.
225 Actuarial survival among these surgically salvaged patie
226 Actuarial survival analysis using Kaplan-Meier curves, C
227 ogistic regression analysis and Kaplan-Meier
actuarial survival analysis.
228 l for the entire group was 9 months, and the
actuarial survival at 1 and 2 years was 42% and 23%, res
229 is 366 days (95% CI 185, not estimable) and
actuarial survival at 1 year is 52%.
230 Actuarial survival at 1 year was 55%, progression-free s
231 Actuarial survival at 1, 5, and 10 years for Group I was
232 Actuarial survival at 10 years from diagnosis of second
233 Actuarial survival at 10 years was 97% (SD 2) in the aut
234 Actuarial survival at 3 years was 70%, and 3-year event-
235 atients (6%) died from lymphoma; the overall
actuarial survival at 3 years was 95%.
236 Actuarial survival at 5 and 10 years was 72.4% (95% conf
237 There was no perioperative mortality and
actuarial survival at 5 years was 94.6%.
238 Actuarial survival at 5, 10, 15, and 20 years was 93% (9
239 Overall
actuarial survival at 7 years was 55%.
240 Actuarial survival at two years was 98.2% among patients
241 Diagnoses were associated with
actuarial survival differences but not good predictions.
242 The overall 20-year
actuarial survival for pediatric liver transplantation i
243 Two-year
actuarial survival for the induction group was 93.2% com
244 re no significant differences in the 10-year
actuarial survival from transplant between groups.
245 For the validation cohort 2, the
actuarial survival from transplant for the M+ group was
246 Actuarial survival of BK-positive grafts was worse than
247 Actuarial survival on support was 72% (95% confidence in
248 The 1-, 3-, and 5-year
actuarial survival rate differed between the study and c
249 The
actuarial survival rate for the total population was 75%
250 2) with 2 late deaths (1.6%), for an overall
actuarial survival rate of 96.3% at 7 years.
251 an, 40 years; range, 20-44 years) the 5-year
actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%)
252 The 5-year
actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%)
253 One-year and 5-year
actuarial survival rates are high, approximately 75% and
254 ts with continuous-flow devices had superior
actuarial survival rates at 2 years (58% vs. 24%, P=0.00
255 Actuarial survival rates at 6 years were as follows: JMM
256 Differences were found in 1-, 3-, and 5-year
actuarial survival rates between the I-CC subgroup and t
257 Five-year
actuarial survival rates for all exposure groups, age-ad
258 The 5-year
actuarial survival rates for more pediatric-specific can
259 The 1-, 2-, and 3-year
actuarial survival rates of all 150 patients were 54%, 1
260 Actuarial survival rates related to prognostic determina
261 applicator (5 cm or 6 cm), the 2- and 3-year
actuarial survival rates were 27% and 17%, respectively.
262 entire group was 14.4 months; 1- and 2-year
actuarial survival rates were 57% and 25%, respectively.
263 The 30-day, 1-year, and 3-year
actuarial survival rates were 77%, 53%, and 43%, respect
264 One and five-year
actuarial survival rates were 85%/64% for adult and 90%/
265 Actuarial survival rates were 91% at 1 year, 88% at 3 ye
266 f 13.3 years, the 10-, 20-, 30-, and 40-year
actuarial survival rates were 93%, 79%, 59%, and 26%, re
267 Actuarial survival rates were 93.3%, 86.4%, and 73.5% at
268 llow-up of 29 months, the 1-, 3-, and 5-year
actuarial survival rates were 97%, 74%, and 58%; median
269 Actuarial survival rates were much lower for blacks than
270 Three year
actuarial survival revealed no difference between groups
271 Kaplan-Meier
actuarial survival was 24 months, with actual 3 and 5 ye
272 who underwent curative resection, the 5-year
actuarial survival was 41%, with a median survival of 48
273 8%/y (95% CI, 0.37-0.62), and 20-year pooled
actuarial survival was 58.7% and freedom from reinterven
274 Actuarial survival was 60+/-12% versus 92+/-5% (P<0.005)
275 , median actuarial TTP was 43 wk, and median
actuarial survival was 70 wk.
276 The
actuarial survival was 70% at 5 years and the aneurysm-r
277 tor of increased all-cause mortality: 1 year
actuarial survival was 79 +/- 5% in the nonfrail group c
278 The 5-year disease-specific
actuarial survival was 79% (78% for patients treated fro
279 ors of increased all-cause mortality: 1-year
actuarial survival was 86 +/- 4% in the nonfrail group c
280 At 10 years, the overall
actuarial survival was 88%, the response rate was 71% wi
281 The overall 4-year estimated
actuarial survival was 89% (95% CI 82-94).
282 Actuarial survival was 97% and 90% (P=0.30), and surviva
283 Actuarial survival was calculated using the Kaplan-Meier
284 When
actuarial survival was estimated, cohorts with < or = 25
285 Actuarial survival was greater in the MMF group compared
286 tcome between matched groups, but the 5-year
actuarial survival was higher in patients with thromboly
287 Actuarial survival was measured from the initiation of r
288 Actuarial survival with freedom from parenteral support
289 The 4-year estimated
actuarial survival with native liver was 51% (42-59%).
290 fully rescued with retransplantation (30-day
actuarial survival, 97.1% SLD vs. 94.1% LRD, P=0.745).
291 The 5-year
actuarial survival, disease-free survival, and bNED rate
292 clophosphamide therapy; at 10 years, overall
actuarial survival, response, and actuarial event-free s
293 , the primary end point of which was 6-month
actuarial survival.
294 perioperative mortality (chi(2)) and 5-year
actuarial survival.
295 fe expectancy of the general population from
actuarial tables: 80 to 84 years (7 years) and > or =85
296 e 27 patients who could be evaluated, median
actuarial TTP was 43 wk, and median actuarial survival w
297 The
actuarial tumor control rate was 98% after 2 years and 9
298 nce rate was 5.4% (13 of 242), with a 5-year
actuarial tumor recurrence-free rate of 0.88 +/- 0.03.
299 estimate the cumulative incidence over time (
actuarial v cumulative calculations), up to 10% of NHL p
300 The
actuarial yearly failure rate was 2.3% for non-Fidelis a